Device Trial Radar · NCT03733730
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Last checked: Nov 20, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,449
Actual
Start
Nov 27, 2018
Primary completion
Oct 14, 2022
Study completion Oct 14, 2022
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, post-approval active surveillance study. The purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an ACRYSOF IQ RESTOR Toric or ACRYSOF IQ RESTOR IOL in the US.
Conditions
- Aphakia
- Presbyopia
- Astigmatism
Interventions
ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOLDevice
Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOLDevice
Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
ACRYSOF IQ RESTOR +2.5 D Multifocal IOLDevice
Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
Cataract SurgeryProcedure
Routine small incision cataract surgery with IOL implantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Eyes With Post-Surgical Intraocular Inflammation - By Eye - Cohort 2Time frame: Day 90 to 180 post implantation, each eye. The second eye was implanted within 20 days of the first eye.
- Rate of Eyes With Post-Surgical Intraocular Inflammation - Overall Eyes - Cohort 2Time frame: Day 90 to 180 post implantation, each eye. The second eye was implanted within 20 days of the first eye.
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Trinity Research Group
Dothan, Alabama
Eye Doctors of Arizona
Phoenix, Arizona
InSight Vision Center
Fresno, California
35 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.